Compare RUN & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RUN | SLNO |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 2.5B |
| IPO Year | 2015 | 2014 |
| Metric | RUN | SLNO |
|---|---|---|
| Price | $17.49 | $51.42 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 10 |
| Target Price | $20.63 | ★ $110.90 |
| AVG Volume (30 Days) | ★ 9.3M | 1.8M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,316,656,000.00 | $98,675,000.00 |
| Revenue This Year | $18.66 | N/A |
| Revenue Next Year | $6.33 | $155.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.79 | N/A |
| 52 Week Low | $5.38 | $41.50 |
| 52 Week High | $22.44 | $90.32 |
| Indicator | RUN | SLNO |
|---|---|---|
| Relative Strength Index (RSI) | 43.75 | 48.33 |
| Support Level | $17.35 | $47.80 |
| Resistance Level | $20.31 | $53.10 |
| Average True Range (ATR) | 1.31 | 2.47 |
| MACD | -0.11 | 1.09 |
| Stochastic Oscillator | 16.70 | 79.48 |
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.